菠萝因子田艳涛主任：胃癌的免疫治疗，你真的了解吗？( 三 )

参考文献：
[1] 中国临床肿瘤学会（CSCO）胃癌诊疗指南,2019.
[2] National Comprehensive Cancer Network. NCCN Guidelines Gastric Cancer Version 1. 2020.
[3] Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer, 2020.
[4] Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol 2016;17:717-726.
[5] Fuchs CS, Doi T, Jang RW, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4:e180013.
[6] Shitara K, ?zgüro?lu M, Bang Y-J, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.Lancet 2018;392:123-133
CheckMate-032 study:
[7] efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 2018;36:2836-2844.
[8] Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390:2461-2471.
[9] Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol 2018;29:2052-2060.
[10] Moehler M, Ryu MH, Dvorkin M, et al. Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. Future Oncol 2019;15:567-577.
_________
上期文章
【菠萝因子田艳涛主任：胃癌的免疫治疗，你真的了解吗？】肺部小结节越来越多，如何避免过度治疗？

菠萝因子 田艳涛主任：胃癌的免疫治疗，你真的了解吗？( 三 )

菠萝因子田艳涛主任：胃癌的免疫治疗，你真的了解吗？( 三 )